Navigation Links
Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
Date:9/28/2011

SAN DIEGO, Sept. 28, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We are looking forward to the results of this proof-of-concept and local tolerability study," said Dr. Francisco Perez, President of the 8th World Congress of Cosmetic Dermatology and principal clinical investigator for the trial. "If HTI-501 proves to be pharmacologically active and well tolerated, it could represent a completely novel approach to the treatment of cellulite."

HTI-501 is a recombinant human proteinase known as cathepsin-L (rHuCAT-L), under development by Halozyme. HTI-501 is being explored as a potential treatment for dermatologic and aesthetic conditions, as well as other indications. As a conditionally active biologic, HTI-501 is designed to allow local degradation of the collagenous fibrous components of the extracellular matrix at the injection site by tightly controlling the extent and duration of enzyme activity once injected into the body. The Phase 1 dose escalation portion of the trial will evaluate a single injection of different HTI-501 formulations into dimpled lesions of the skin followed by a Phase 2 portion of the trial where multiple lesions will be targeted with the optimal dose and formulation. Up to 48 and 76 subjects may be enrolled in the Phase 1 and Phase 2 portions of the trial, respectively
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... COLUMBIA, Md. (PRWEB) March 02, 2015 ... poster sessions and present on LCMS and marijuana analysis ... takes place March 8 to 12 at the Ernest ... , Attendees can stop by booth 3121 to discuss ... how the company’s innovative, proven products help save time, ...
(Date:3/2/2015)... Resilinc released online today its ... summarizes and analyzes nearly 700 unique supply chain notifications ... global event monitoring and alert reporting service. Supply chain ... period of the email service to receive early warnings ... impact revenue, market share, customer satisfaction, and shareholder value. ...
(Date:3/2/2015)... March 2, 2015 VLP Therapeutics, LLC. ... company focusing on the research and development of ... agents based upon a novel and proprietary vaccine ... Sciences Impact Grant Award from the Montgomery County ... by MCDED, is awarded to life sciences companies ...
(Date:3/2/2015)... March 2, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics, today announced that it ... Healthcare Conference in Miami, FL at the Loews Miami Beach ... officer of Pfenex, will provide an overview of ... 12th at 9:00 am ET. A live audio webcast and ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 2Resilinc Publishes 2014 EventWatch™ Supply Chain Disruption Annual Report 3VLP Therapeutics Wins the 2015 Life Sciences Impact Grant Award from the Montgomery County Department of Economic Development 2
... , , , BEIJING , Feb. 8 ... in-vitro,diagnostic ("IVD") company, today announced that it will participate at the,following investor conferences in March 2010 : ... Location, ... Hotel, China Investment ...
... , NEW YORK , Feb. 8 ... relations and corporate communications for domestic and international clients, announced ... have joined as Managing Directors. , “Lisa and ... serve our clients well,” said Lynn Morgen , co-founder ...
... , , , , ... 3SBio Inc. (Nasdaq:, SSRX ) ("3SBio" or "the Company"), ... developing, manufacturing and marketing,biopharmaceutical products, today announced a collaboration ... commercialize its,Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2MBS Value Partners Hires Two New Senior Staff Members 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... CORVALLIS, Ore. Researchers at Oregon State University for the ... overfishing and nitrate pollution can help destroy coral reefs ... bring with it unwanted pathogens, choke off oxygen and disrupt ... big enough to essentially smother corals. They can get out ...
... who take the time to read food labels are ... from a recently released study authored by Steven T. ... of Agriculture,s Department of Agricultural and Resource Economics, in ... Compostela in Spain, the University of Arkansas and the ...
... press release is available in Spanish . ... Development, NEIKER-Tecnalia, and the National Institute of Agricultural Research in ... of ,black dead arm, (BDA) on grapevine leaves are, in ... and BDA are diseases that affect the trunk of ...
Cached Biology News:The 'slippery slope to slime': Overgrown algae causing coral reef declines 2NEIKER and INRA discover that BDA symptoms in grapevine leaves are a sign of esca 2
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
Biology Products: